145 related articles for article (PubMed ID: 29434001)
41. Investigations of prion and virus safety of a new liquid IVIG product.
Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
[TBL] [Abstract][Full Text] [Related]
42. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
[TBL] [Abstract][Full Text] [Related]
43. Phage passage after extended processing in small-virus-retentive filters.
Lute S; Bailey M; Combs J; Sukumar M; Brorson K
Biotechnol Appl Biochem; 2007 Jul; 47(Pt 3):141-51. PubMed ID: 17286554
[TBL] [Abstract][Full Text] [Related]
44. Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration.
Cetlin D; Pallansch M; Fulton C; Vyas E; Shah A; Sohka T; Dhar A; Pallansch L; Strauss D
Biotechnol Prog; 2018 Sep; 34(5):1213-1220. PubMed ID: 30194917
[TBL] [Abstract][Full Text] [Related]
45. Adapting virus filtration to continuous processing: Effects of product and process variability on filtration performance.
Kozaili J; Rayfield W; Gospodarek A; Brower M; Strauss D
Biotechnol Prog; 2024; 40(2):e3407. PubMed ID: 38146086
[TBL] [Abstract][Full Text] [Related]
46. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
[TBL] [Abstract][Full Text] [Related]
47. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
Romberg V; Hoefferer L; El Menyawi I
Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
[TBL] [Abstract][Full Text] [Related]
48. Liquid pasteurization of an immunoglobulin preparation without stabilizer: effects on its biological and biochemical properties.
Bridonneau P; Marcilly H; Vernois-Martin M; Goigoux P; Bourdel V; Laulan A; Deramoudt FX; Desmadril M; Sitbon M; Basuyaux B; Steinbuch M; Schmitthaeusler R
Vox Sang; 1996; 70(4):203-9. PubMed ID: 9123924
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
51. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
52. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
53. Aggregate Removal Nanofiltration of Human Serum Albumin Solution Using Nanocellulose-Based Filter Paper.
Wu L; Mantas A; Gustafsson S; Manukyan L; Mihranyan A
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32668723
[TBL] [Abstract][Full Text] [Related]
54. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
[TBL] [Abstract][Full Text] [Related]
55. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
56. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
57. Variability of parvovirus B19 genotype 2 in plasma products with different compositions in the inactivation sensitivity by liquid-heating.
Tsujikawa M; Nishigaki H; Yoshikawa M; Furuki R; Takahashi K; Adan-Kubo J; Shimamura Y; Urayama T; Hattori S; Sakai K; Yunoki M; Ikuta K
Vox Sang; 2012 Feb; 102(2):93-9. PubMed ID: 21781123
[TBL] [Abstract][Full Text] [Related]
58. Development of small-scale models to understand the impact of continuous downstream bioprocessing on integrated virus filtration.
Lute S; Kozaili J; Johnson S; Kobayashi K; Strauss D
Biotechnol Prog; 2020 May; 36(3):e2962. PubMed ID: 31945257
[TBL] [Abstract][Full Text] [Related]
59. Normal-flow virus filtration: detection and assessment of the endpoint in bio-processing.
Bolton G; Cabatingan M; Rubino M; Lute S; Brorson K; Bailey M
Biotechnol Appl Biochem; 2005 Oct; 42(Pt 2):133-42. PubMed ID: 15901236
[TBL] [Abstract][Full Text] [Related]
60. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Hougardy V; de Launoit Y; Laub R
Transfusion; 2004 Sep; 44(9):1340-3. PubMed ID: 15318858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
